Figure 1

Mean changes in BPRS scores during six weeks of treatment in olanzapine long-acting injection and oral olanzapine studies of acute schizophrenia. In the LAI study, all 3 olanzapine LAI treatment groups showed statistically greater reductions vs. placebo by day 3 (p = .05) and for the remainder of the study. In oral olanzapine study 1, the 10- and 15-mg/day olanzapine groups and the haloperidol group showed statistically greater reductions vs. placebo at week 1 and beyond (p = .05). In oral study 2, no groups separated statistically from the 1-mg reference dose although the overall pattern of symptom reductions appeared similar to those in the other studies. In oral olanzapine study 3, the 10-mg/day treatment group showed a significant difference vs. placebo at week 6 (p = .04).